Adaptimmune Sales Jump 59 Percent
Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a biotechnology company specializing in engineered T-cell therapies for cancer, released its second-quarter earnings on August 13, 2025, covering results for the three months ended June 30. The key headline: earnings per share (GAAP) came in better than expected at $(0.02), beating analyst estimates by 52.4%. Revenue (GAAP) reached $13.7 million, surpassing the forecast of $8.6 million by $5.1 million (59.3% above estimates). Despite this beat, GAAP revenue fell from $128.2 million in Q2 2024, reflecting the loss of major development revenue. The quarter saw significant restructuring actions and an asset sale that will fundamentally reshape the business. Overall, while product sales exceeded expectations (GAAP basis) thanks to strong early commercialization, Adaptimmune’s financial profile has become more limited and increasingly reliant on milestone payments and pipeline prospects.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Adaptimmune is a commercial-stage biopharmaceutical company developing cell therapies that direct patients’ own immune cells to target and attack cancer. Its current success centers on its lead product, TECELRA, an engineered T-cell therapy approved by the U.S. Food and Drug Administration for adults with unresectable or metastatic synovial sarcoma, a rare skeletal muscle tumor.
Source Fool.com
